173 related articles for article (PubMed ID: 22208667)
1. Role of glutamate 64 in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Wang J; Sklenak S; Liu A; Felczak K; Wu Y; Li Y; Yan H
Biochemistry; 2012 Jan; 51(1):475-86. PubMed ID: 22208667
[TBL] [Abstract][Full Text] [Related]
2. Product release is rate-limiting in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Yao L; Li Y; Wu Y; Liu A; Yan H
Biochemistry; 2005 Apr; 44(15):5940-7. PubMed ID: 15823054
[TBL] [Abstract][Full Text] [Related]
3. Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.
Stolworthy TS; Korkegian AM; Willmon CL; Ardiani A; Cundiff J; Stoddard BL; Black ME
J Mol Biol; 2008 Mar; 377(3):854-69. PubMed ID: 18291415
[TBL] [Abstract][Full Text] [Related]
4. Product release mechanism and the complete enzyme catalysis cycle in yeast cytosine deaminase (yCD): A computational study.
Zhao Y; She N; Zhang X; Wang C; Mo Y
Biochim Biophys Acta Proteins Proteom; 2017 Aug; 1865(8):1020-1029. PubMed ID: 28478051
[TBL] [Abstract][Full Text] [Related]
5. Combined QM(DFT)/MM molecular dynamics simulations of the deamination of cytosine by yeast cytosine deaminase (yCD).
Zhang X; Zhao Y; Yan H; Cao Z; Mo Y
J Comput Chem; 2016 May; 37(13):1163-74. PubMed ID: 26813441
[TBL] [Abstract][Full Text] [Related]
6. Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference.
Mahan SD; Ireton GC; Stoddard BL; Black ME
Biochemistry; 2004 Jul; 43(28):8957-64. PubMed ID: 15248753
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.
Johnson AJ; Ardiani A; Sanchez-Bonilla M; Black ME
Cancer Gene Ther; 2011 Aug; 18(8):533-42. PubMed ID: 21394105
[TBL] [Abstract][Full Text] [Related]
8. Transduction of yeast cytosine deaminase mediated by HIV-1 Tat basic domain into tumor cells induces chemosensitivity to 5-fluorocytosine.
Lee H; Ryu J; Kim KA; Lee KS; Lee JY; Park JB; Park J; Choi SY
Exp Mol Med; 2004 Feb; 36(1):43-51. PubMed ID: 15031670
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution.
Ko TP; Lin JJ; Hu CY; Hsu YH; Wang AH; Liaw SH
J Biol Chem; 2003 May; 278(21):19111-7. PubMed ID: 12637534
[TBL] [Abstract][Full Text] [Related]
10. A molecular dynamics exploration of the catalytic mechanism of yeast cytosine deaminase.
Yao L; Sklenak S; Yan H; Cukier RI
J Phys Chem B; 2005 Apr; 109(15):7500-10. PubMed ID: 16851861
[TBL] [Abstract][Full Text] [Related]
11. Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy.
Mahan SD; Ireton GC; Knoeber C; Stoddard BL; Black ME
Protein Eng Des Sel; 2004 Aug; 17(8):625-33. PubMed ID: 15381761
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of a transition-state analogue at the active site of yeast cytosine deaminase: importance of proton transfers.
Xu Q; Guo H; Gorin A; Guo H
J Phys Chem B; 2007 Jun; 111(23):6501-6. PubMed ID: 17506543
[TBL] [Abstract][Full Text] [Related]
13. Catalytic mechanism of yeast cytosine deaminase: an ONIOM computational study.
Sklenak S; Yao L; Cukier RI; Yan H
J Am Chem Soc; 2004 Nov; 126(45):14879-89. PubMed ID: 15535715
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional structure and catalytic mechanism of cytosine deaminase.
Hall RS; Fedorov AA; Xu C; Fedorov EV; Almo SC; Raushel FM
Biochemistry; 2011 Jun; 50(22):5077-85. PubMed ID: 21545144
[TBL] [Abstract][Full Text] [Related]
15. PEGylation of yeast cytosine deaminase for pretargeting.
Xiong MP; Kwon GS
J Pharm Sci; 2005 Jun; 94(6):1249-58. PubMed ID: 15858841
[TBL] [Abstract][Full Text] [Related]
16. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
Hamstra DA; Lee KC; Tychewicz JM; Schepkin VD; Moffat BA; Chen M; Dornfeld KJ; Lawrence TS; Chenevert TL; Ross BD; Gelovani JT; Rehemtulla A
Mol Ther; 2004 Nov; 10(5):916-28. PubMed ID: 15509509
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of a novel chitosan based E. coli cytosine deaminase nanocomposite for potential application in prodrug enzyme therapy.
Yata VK; Ghosh SS
Biotechnol Lett; 2011 Jan; 33(1):153-7. PubMed ID: 20960222
[TBL] [Abstract][Full Text] [Related]
18. A combined ONIOM quantum chemical-molecular dynamics study of zinc-uracil bond breaking in yeast cytosine deaminase.
Yao L; Yan H; Cukier RI
J Phys Chem B; 2006 Dec; 110(51):26320-6. PubMed ID: 17181291
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Yi BR; Kim SU; Kim YB; Lee HJ; Cho MH; Choi KC
Oncol Rep; 2012 Jun; 27(6):1823-8. PubMed ID: 22426744
[TBL] [Abstract][Full Text] [Related]
20. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
Hirschowitz EA; Ohwada A; Pascal WR; Russi TJ; Crystal RG
Hum Gene Ther; 1995 Aug; 6(8):1055-63. PubMed ID: 7578418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
